- Home
- ALNY vs GEHC Comparison
ALNY vs GEHC Comparison
Compare ALNY & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- GEHC
- Stock Information
- Founded
- ALNY 2002
- GEHC 1892
- Country
- ALNY United States
- GEHC United States
- Employees
- ALNY N/A
- GEHC N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- GEHC Computer Software: Prepackaged Software
- Sector
- ALNY Health Care
- GEHC Technology
- Exchange
- ALNY Nasdaq
- GEHC Nasdaq
- Market Cap
- ALNY 33.2B
- GEHC 36.2B
- IPO Year
- ALNY 2004
- GEHC N/A
- Fundamental
- Price
- ALNY $264.99
- GEHC $87.34
- Analyst Decision
- ALNY Buy
- GEHC Buy
- Analyst Count
- ALNY 24
- GEHC 14
- Target Price
- ALNY $299.09
- GEHC $96.00
- AVG Volume (30 Days)
- ALNY 643.5K
- GEHC 3.2M
- Earning Date
- ALNY 02-13-2025
- GEHC 02-13-2025
- Dividend Yield
- ALNY N/A
- GEHC 0.16%
- EPS Growth
- ALNY N/A
- GEHC 8.27
- EPS
- ALNY N/A
- GEHC 3.65
- Revenue
- ALNY $2,094,795,000.00
- GEHC $19,559,000,000.00
- Revenue This Year
- ALNY $24.87
- GEHC $2.70
- Revenue Next Year
- ALNY $18.53
- GEHC $3.90
- P/E Ratio
- ALNY N/A
- GEHC $23.93
- Revenue Growth
- ALNY 21.54
- GEHC 1.43
- 52 Week Low
- ALNY $141.98
- GEHC $71.31
- 52 Week High
- ALNY $304.39
- GEHC $94.55
- Technical
- Relative Strength Index (RSI)
- ALNY 61.89
- GEHC 66.03
- Support Level
- ALNY $245.69
- GEHC $82.86
- Resistance Level
- ALNY $256.93
- GEHC $86.25
- Average True Range (ATR)
- ALNY 9.38
- GEHC 2.06
- MACD
- ALNY 2.95
- GEHC 0.68
- Stochastic Oscillator
- ALNY 99.91
- GEHC 97.21
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).